Kyong Hwa Park

Articles by Kyong Hwa Park

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028

KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS

Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer

How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?

Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer